Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270132 | 0.78 | — | — | |
| SCHEMBL6720465 | 0.71 | — | — | |
| SCHEMBL94152 | 0.70 | — | — | |
| SCHEMBL27898394 | 0.70 | LMNA (0.35) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL5014969 | 0.70 | SLC22A6 (0.41) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL4682735 | 0.69 | — | — | |
| SCHEMBL2354293 | 0.69 | TET2 (0.33) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL1407281 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL10681763 | 0.69 | TET2 (0.33) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL5883451 | 0.69 | TET2 (0.33) | ALDH1A1LMNAMAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809498-B2 | Pepstatin A derivatives | FREIE UNIVERSITAET BERLIN (DE) | 2014-08-19 | — | — | US | disclosed |
| EP-2283030-B1 | PEPSTATIN A DERIVATIVES | UNIV BERLIN FREIE (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-20120016103-A1 | PEPSTATIN A DERIVATIVES | FREIE UNIVERSITAET BERLIN | 2012-01-19 | — | — | US | disclosed |
| EP-2283030-A1 | PEPSTATIN A DERIVATIVES | Freie Universität Berlin (DE) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009133188-A1 | PEPSTATIN A DERIVATIVES | FREIE UNIVERSITÄT BERLIN (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016103-A1 | PEPSTATIN A DERIVATIVES | PEPD, ANPEP, VIP | S1PR2 2093/4885S1PR4 2607/4885S1PR1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.